[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psychotropic-drugs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psychotropic-drugs":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,63,85,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":44,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100573936","phase-3-nebulized-ketamine-for-the-treatment-of-major-depressive-disorder-100573936",false,"NCT06752759","Nebulized Ketamine for the Treatment of Major Depressive Disorder","Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial","Inclusion Criteria:\n\n* All individuals 18 years and older with a Montgomery-Asberg Depression Rating Scale score (MADRS) ≥ 20\n* Must have a diagnosis of moderate to severe Major Depressive Disorder (MDD)\n* Structured Clinical Interview for DSM-5 (SCID-5) will be performed to confirm MDD diagnosis\n\nExclusion Criteria:\n\n* Adult patients with an allergy to Ketamine\n* Adult patients with an allergy to Midazolam\n* Individuals with a history of mania\u002Fhypomania or diagnosis of bipolar disorder\n* Patients on lithium and\u002For lamotrigine therapy\n* Recent or current homicidal ideation with an intent to act\n* MDD with psychotic features or current or past diagnosis of a psychotic disorder\n* No substance use disorder in the preceding 3 months except nicotine or caffeine or a positive urine screen for substances (except cannabis)\n* Diagnosis of obsessive-compulsive disorder, antisocial personality disorder, borderline personality disorder, posttraumatic stress disorder, intellectual disability, altered mental status, pregnant or breastfeeding patients,\n* Patients on \\> 2 medications for hypertension\n* Patients with uncontrolled hypertension (BP \\>140 mm Hg systolic and\u002For \\>90 mm Hg diastolic on two separate readings at the time of screening)\n* Body weight of \\> 150kg\n* Patients with history of congestive cardiac failure\n* Day of presentation, patients with unstable vital signs (systolic blood pressure \\\u003C90 or\\>160 mm Hg, pulse rate \\\u003C50 or \\>150 beats\u002Fmin, and respiration rate \\\u003C10 or \\>30 breaths\u002Fmin)\n* Consumption of opioids within 24 hours of drug administration\n* Acutely intoxicated patients will also be excluded","ALL","18 Years","88 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Severe Depression","Moderate Depression","Ketamine","Midazolam","Peripheral Nervous System Agents","Central Nervous System Agents","Neurotransmitter Agents","Physiologic Effects of Drugs","Sensory System Agents","Analgesics, Non-Narcotic","Anti-Inflammatory Agents, Non-Steroidal","Depressive Symptom","Hypnotics and Sedatives","Anti-anxiety Agents","Tranquilizing Agents","Psychotropic Drugs","Anesthetics Agent",[45,46,29,30,31,35,47,48,49],"Maimonides Medical Center","Psychiatry","Anesthetics, Dissociative","Nebulized Medications for depression","GABA Agents","RECRUITING","2026-04-21",{"date":53,"type":54},"2026-04-24","ACTUAL",{"date":56,"type":54},"2024-10-16",{"date":58,"type":21},"2027-09-30",{"name":60,"class":61},"Theresa Jacob, PhD, MPH","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":62},"100601598","association-between-intake-of-psychotropic-medications-and-risk-of-falls-in-older-adults-100601598","NCT07112573","Association Between Intake of Psychotropic Medications and Risk of Falls in Older Adults","Inclusion Criteria:\n\n* patients (males and females) aged ≥ 60 years old patients who accept to participate in the study\n\nExclusion Criteria:\n\n* Patients with malignancy Bedridden patients","60 Years",{"count":71,"type":21},398,"OBSERVATIONAL","The aim of the study is to assess the association between intake of psychotropic medications and increased risk of falls in older adults discharged from Ain Shams University Geriatric Hospital as a primary outcome and incident fractures that may occur as a secondary outcome of such fall.",[75,42],"Falls (Accidents) in Old Age","2026-03-14",{"date":78,"type":54},"2026-03-17",{"date":80,"type":54},"2025-07-01",{"date":82,"type":21},"2026-06",{"name":84,"class":61},"Ain Shams University",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":92,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":96,"studyType":72,"phases":4,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":62},"100151717","national-pregnancy-registry-for-psychiatric-medications-100151717","NCT01246765","National Pregnancy Registry for Psychiatric Medications","Inclusion Criteria:\n\n* Pregnant women\n* Age 18-45\n* Subjects will be willing to participate over the phone\n* Subjects will be able to provide informed consent\n\nExclusion Criteria:\n\n* Women who have completed their pregnancy\n* Women who are planning to become pregnant\n* Women who are not taking any psychiatric medications and\u002For have no history of psychiatric illness",true,"FEMALE","45 Years",{"count":95,"type":21},5000,"15 Months","The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.",[99,42],"Pregnant Women",[101,102,103,104,105,106,107],"Pregnancy","Medication use during pregnancy","Psychiatric medications","ADHD","Atypical Antipsychotics","Antidepressants","Sedative Hypnotics","2025-10-22",{"date":110,"type":54},"2025-10-24",{"date":112,"type":54},"2008-11",{"date":114,"type":21},"2033-12",{"name":116,"class":61},"Massachusetts General Hospital",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":91,"sex":16,"minAge":125,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":62},"100532339","drugs-experience-for-adolescents-with-anorexia-100532339","NCT06211517","Drugs Experience for Adolescents With Anorexia","Subjective Experience of Psychotropic Drugs Among Adolescents (Their Parents and Professionals) With Anorexia Nervosa","E3P","Inclusion Criteria:\n\nAdolescents :\n\n* Aged 12 to 25 years\n* Suffering from anorexia nervosa (restrictive or mixed) according to DSM-5 (Diagnostic and Statistical Manual) criteria\n* Received psychotropic drugs (antidepressant treatment and\u002For APA) during their care, either ongoing or discontinued before this study started\n\nParents of adolescents suffering from anorexia nervosa for whom a psychotropic drug has been prescribed and whose adolescents meet inclusion criteria\n\nHealthcare Professionals working with adolescents suffering from eating disorders\n\nExclusion Criteria:\n\nAdolescents :\n\n* Atypical eating disorder that does not meet the DSM-5 criteria for restrictive or mixed anorexia nervosa\n* BMI\\\u003C15\n* Prescription of an antidepressant other than an SSRI (Selective Serotonin Reuptake Inhibitor)\n* Prescription of an APA for the indication of psychotic symptoms","12 Years",{"count":127,"type":21},90,"The purpose of this study is to access to the experiences of adolescents, their parents and healthcare professionals regarding psychotropic drugs in anorexia nervosa.\n\nNo preconceived ideas (according to qualitative methods) but a question: what are the participants' perceptions and experiences of psychotropic drugs in anorexia nervosa? In an adolescent medicine department.",[130,42,131],"Anorexia Nervosa","Adolescent",[133,134,135,136,137],"Adolescents","Anorexia nervosa","Psychotropic drugs","Qualitative research","Thematic analysis","2025-09-05",{"date":140,"type":54},"2025-09-12",{"date":142,"type":54},"2024-05-20",{"date":144,"type":21},"2027-12",{"name":146,"class":61},"Assistance Publique - Hôpitaux de Paris"]